Opioid use disorder (OUD) is a treatable medical condition. Three medications are FDA-approved specifically for its treatment: buprenorphine, methadone, and naltrexone. Collectively they are referred to as Medications for Opioid Use Disorder (MOUD) – sometimes also called medication-assisted treatment (MAT).
SAMHSA identifies these three as the evidence-based cornerstone of OUD treatment. Used in combination with counseling and support services, they significantly reduce cravings, prevent relapse, lower overdose mortality, and improve long-term outcomes. [1]
This page provides a clear overview of each medication, a neutral comparison, and answers to common questions – including the one asked most often: “Is this just replacing one addiction with another?”
Buprenorphine, methadone, and naltrexone are the three FDA-approved medications for OUD. All three reduce the risk of relapse and overdose death. They work through different mechanisms and suit different clinical situations. None is universally “best” – the right choice depends on individual circumstances and should be made with a clinician.
What Is MOUD?
MOUD refers to the use of FDA-approved medications – in combination with counseling and psychosocial support – to treat opioid use disorder. The goal is not simply to manage withdrawal symptoms, but to address the longer-term neurobiological and behavioral dimensions of OUD.
MOUD is grounded in decades of research. It is the standard of care recommended by SAMHSA, the American Society of Addiction Medicine (ASAM), and major international health bodies. [1, 2]
Why Medication May Be Recommended
After acute withdrawal, many people return to opioid use – not because of weak willpower, but because:
- Cravings driven by changes in brain reward circuits persist long after physical withdrawal resolves
- Stress, environmental cues, and emotional triggers can produce powerful urges to use
- Tolerance drops during abstinence, meaning a return to use at a previous dose can be fatal
- The underlying neurobiological adaptations of OUD do not fully reverse in a short timeframe
MOUD medications work with the brain’s opioid receptor system – rather than demanding that the system immediately normalize – to reduce cravings and block the reinforcing effects of illicit opioids. Evidence consistently shows that MOUD reduces overdose deaths, reduces illicit opioid use, and improves quality of life. [1]
Buprenorphine
Buprenorphine is a partial opioid agonist – it activates mu-opioid receptors, but less strongly than full agonists like heroin or oxycodone. This partial activation is enough to reduce cravings and withdrawal symptoms without producing significant euphoria at therapeutic doses. It also has a “ceiling effect” on respiratory depression, making it much safer in overdose than full agonists.
- Common formulations: Sublingual film (Suboxone – buprenorphine/naloxone), sublingual tablets (Subutex), monthly injectable (Sublocade), six-month implant (Probuphine).
- Naloxone combination: Most formulations combine buprenorphine with naloxone to deter injection misuse. When taken as directed sublingually, naloxone is minimally absorbed and has no meaningful effect.
- Access: Can be prescribed by physicians, nurse practitioners, and physician assistants – including office-based and telehealth settings. Since 2023, the X-waiver requirement has been eliminated in the U.S.
- Induction: Buprenorphine must be initiated when the person is in mild-to-moderate withdrawal to avoid precipitated withdrawal.
- Duration: Can be used short-term for withdrawal management or long-term for OUD treatment. Evidence generally supports longer duration of treatment for better outcomes.
SAMHSA describes buprenorphine as reducing illicit opioid use and increasing treatment retention. [1] See: Buprenorphine Explained
Methadone
Methadone is a full opioid agonist with a long half-life (24-36+ hours). At stable therapeutic doses, it eliminates withdrawal symptoms and reduces cravings throughout the day without producing euphoria – because blood levels remain stable rather than spiking.
- Treatment setting: For OUD treatment, methadone must be dispensed through federally licensed Opioid Treatment Programs (OTPs), typically as a daily oral dose administered at a clinic.
- Stability: Stable patients may earn take-home doses over time, reducing the burden of daily clinic visits.
- Safety considerations: Methadone has a narrow therapeutic window and can affect heart rhythm at higher doses. Dose adjustments require clinical monitoring.
- Long-term use: Research supports long-term methadone maintenance. Stopping methadone requires a supervised, gradual taper.
- Who it may suit: People who have not responded to buprenorphine, those requiring a more structured treatment setting, or those with more severe OUD.
See: Methadone Explained
Naltrexone
Naltrexone is an opioid antagonist – it blocks opioid receptors entirely, preventing any opioid from producing its effects. Unlike buprenorphine and methadone, it has no opioid agonist activity and cannot be misused to get high.
- Formulations: Oral tablet (ReVia – daily) or extended-release injectable (Vivitrol – monthly).
- Opioid-free requirement: A person must be fully opioid-free for 7-10 days, longer for methadone, before initiation.
- No physical dependence: Naltrexone does not produce physical dependence. Stopping it does not cause withdrawal.
- Mechanism: By blocking opioid receptors, naltrexone removes the reinforcing effect of opioids.
- Adherence: Oral naltrexone can be a challenge. The monthly injectable formulation removes the need for daily dosing.
- Who it may suit: People who are highly motivated, have completed opioid detox, prefer a non-opioid treatment, or have professional/legal reasons to avoid agonist medications.
See: Naltrexone Explained
Comparing the Three Medications
No (requires prior detox)
Physical dependence produced
Long-term use supported by evidence
Office-based, telehealth, ED
Licensed OTP clinic (daily)
Office-based, monthly injectable
Opioid-free period required
Must be in mild withdrawal
7-10+ days fully opioid-free
Lower (requires monitoring)
Highest (no agonist activity)
"Is MOUD Just Replacing One Addiction With Another?"
This is the most common question – and the most important one to address honestly.
The short answer: No. SAMHSA explicitly describes MOUD medications as evidence-based treatments, not as substituting one drug for another. [1]
Here is why the comparison does not hold up:
- OUD involves compulsive, harmful use despite negative consequences. A person on a stable therapeutic dose is taking a medication as prescribed that allows them to function normally.
- The neurobiological goals are different. MOUD medications stabilize the opioid receptor system at a consistent level, rather than producing spikes and crashes.
- Functional outcomes improve. Research shows people on MOUD have better employment, family, and health outcomes compared to abstinence-only approaches.
- Mortality decreases significantly. MOUD reduces overdose deaths. The “replacement addiction” framing can contribute to preventable deaths when used to withhold effective treatment.
The more accurate analogy is insulin for diabetes or blood pressure medication for hypertension – a chronic condition managed with medication that allows the person to live a healthy, functional life.
What Happens If Someone Wants to Stop MOUD?
This is a decision that should be made with careful clinical planning – not abruptly.
- Stopping buprenorphine or methadone abruptly will produce withdrawal and significantly increase relapse risk.
- A supervised taper is the standard approach, individualized to the person’s situation.
- There is no standard “right” duration of MOUD. Some people choose to continue long-term; others eventually taper successfully. Both are valid outcomes.
- The decision to discontinue MOUD should be driven by the person’s own goals, medical situation, and readiness, assessed collaboratively with a clinician.
Abrupt discontinuation significantly increases the risk of relapse and, because tolerance drops rapidly, the risk of a fatal overdose on return to use.
MOUD vs. Detox
Detox (withdrawal management) and MOUD are not equivalent. Detox manages the physical symptoms of withdrawal – it does not treat opioid use disorder. Evidence consistently shows that detox alone, without ongoing MOUD or other treatment, is associated with high rates of return to use. [2]
Detox can be an important first step – but for most people with OUD, it should be followed by ongoing treatment, of which MOUD is the most evidence-supported form. See: MOUD vs. Detox: What’s the Difference?
Questions to Ask a Clinician
If you are considering MOUD, these questions can help you make an informed decision:
- Which medication would you recommend for my situation, and why?
- What does the induction process look like – what do I need to do first?
- How will we monitor my progress and adjust the dose?
- What are the most common side effects I should expect?
- How long do most of your patients stay on this medication?
- What happens if I miss a dose or want to stop?
- What counseling or support services do you recommend alongside medication?
- What does discontinuation look like when/if I choose to stop?
For a comprehensive preparation guide: How to Prepare for a Conversation With a Treatment Provider
Finding Treatment
- SAMHSA Helpline: 1-800-662-4357 (free, confidential, 24/7)
- FindTreatment.gov: findtreatment.gov – treatment program locator
- SAMHSA Buprenorphine Prescriber Locator: samhsa.gov
Key Takeaways
Related Resources
Sources
- SAMHSA. Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP) 63. 2021. SAMHSA.gov
- Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies – tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063-2066. PubMed
- Mattick RP, et al. Methadone maintenance versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009. PubMed
- CDC. Evidence-Based Overdose Prevention Strategies. CDC.gov
This page provides general educational information. MOUD decisions should be made in collaboration with a licensed healthcare provider.
